Answers are grounded in this paper and cite their sources.
BACKGROUND: For half the world's population, headaches represent a major health burden that cripples productivity and mental well-being. While newer CGRP-targeted drugs have shown promise for migraines, less is known about how neuromodulation techniques might help with other types of headaches. We designed this umbrella review to investigate how safe and effective occipital nerve stimulation (ONS) is for different headache disorders, and to grade the overall strength of the existing evidence. METHODS: We looked through PubMed, Scopus, and the Cochrane Library (from inception to November 12, 2025) for relevant systematic reviews. Two reviewers worked separately to select studies and extract data. We focused on pain intensity as the main outcome, but also looked at safety, patient satisfaction, and quality of life. We used AMSTAR 2 to assess the quality of the included studies. RESULTS: A total of 207 records were identified, of which nine systematic reviews met the inclusion criteria. ONS was most frequently evaluated in migraine (n = 6), followed by occipital neuralgia (n = 4), cluster headache (n = 3), hemicrania continua (n = 3), SUNCT/SUNA (n = 2), paroxysmal hemicrania (n = 2), cervicogenic headache (n = 1), posttraumatic headache (n = 1), and C2-mediated occipital headache (n = 1). CONCLUSION: Current evidence is insufficient to determine the overall effectiveness of occipital nerve stimulation (ONS) across different headache disorders. Review quality varied, and results differed by condition, with more favorable outcomes for occipital neuralgia and cluster headache. Findings for migraine remain inconsistent, and data for other disorders are preliminary. Hardware-related complications also remain a notable concern.
No takes yet. Share an insight, caveat, or question.
Tungushpayev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: